Printer Friendly

TEXAS BIOTECHNOLOGY FILES FOR INITIAL PUBLIC OFFERING

 HOUSTON, Nov. 12 /PRNewswire/ -- Texas Biotechnology Corporation ("TBC") announced today that it has filed a registration statement relating to an initial public offering 2.5 million units (excluding an over-allotment option), each unit consisting of one share of common stock and one redeemable common stock purchase warrant, all of which will be sold by Texas Biotechnology. The units are to be offered through a syndicate of underwriters managed by D. Blech & Company, Incorporated.
 Texas Biotechnology Corporation, a biopharmaceutical company, applies innovative drug discovery techniques and its specialized knowledge of the role of vascular cell biology in cardiovascular disease to the design and development of novel pharmaceutical compounds. The company's research and development programs focus on the development of small molecule drugs that prevent blood clot formation (thrombosis), the proliferation of smooth muscle cells at the site of vascular injury (vascular proliferative disease) and inflammatory responses to vessel injury (vascular inflammation).
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 A copy of the preliminary prospectus relating to the public offering may be obtained from the D. Blech & Company, Incorporated, Prospectus Department at 800-669-4351.
 -0- 11/12/93
 /CONTACT: David B. McWilliams, president and CEO, or Stephen L. Mueller, director, finance and administration of Texas Biotechnology Corporation, 713-796-8822; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180/


CO: Texas Biotechnology Corporation ST: Texas IN: MTC SU: OFR

WB-TW -- NY080 -- 3859 11/12/93 16:20 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 12, 1993
Words:325
Previous Article:AMERICAN REAL ESTATE PARTNERS, L.P. REPORTS THIRD QUARTER AND NINE MONTH RESULTS
Next Article:SOUTHERN INVESTORS SERVICE COMPANY, INC. REPORTS THIRD QUARTER RESULTS FOR 1993
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters